SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Drug Pricing and Value in Oncology
9 references·1 citing·35 second hop
Drug Pricing and Value in Oncology (2010)Drug Pricing and Value in OncologyPharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement (2013)Pharmaceutical Pricing in Eme…Effects of Regulation on Drug Launch and Pricing in Interdependent Markets (2012)Effects of Regulation on Drug…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Limits on Medicare's Ability …Pharmaceutical Price Controls and Entry Strategies (2007)Pharmaceutical Price Controls…Prices And Availability Of Biopharmaceuticals: An International Comparison (2006)Prices And Availability Of Bi…Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients? (2006)Does Reimbursement Influence …Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)The impact of price regulatio…Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Prices And Availability Of Ph…Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2012)Value-Based Differential Pric…Generic Entry and the Pricing of Pharmaceuticals (1997)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries (2017)Innovative Approaches to Increase Access to Medicines in Developing Countries (2017)Pooled procurement of drugs in low and middle income countries (2021)Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy (1993)The Regulation of Entry (2000)Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry (2004)International Prices And Availability Of Pharmaceuticals In 2005 (2008)Patents and the Global Diffusion of New Drugs (2015)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments (1973)A Method for Minimizing the Impact of Distributional Assumptions in Econometric Models for Duration Data (1984)The price of innovation: new estimates of drug development costs (2003)ALFRED MARSHALL LECTURE INTELLECTUAL PROPERTY RIGHTS PROTECTION IN DEVELOPING COUNTRIES: THE CASE OF PHARMACEUTICALS (2010)Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market (2020)A Contribution to the Theory of Taxation (1927)Cross-national price differences for pharmaceuticals: how large, and why? (2000)Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States (2014)General Equilibrium Computations of the Marginal Welfare Costs of Taxes in the United States.Optimal Departures from Marginal Cost Pricing (2005)Global Health Impact (2020)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Contemporary generic market in Japan – key conditions to successful evolution (2014)Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues (2018)Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? (2020)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)Support of cancer patients' spiritual needs and associations with medical care costs at the end of life (2011)Pharmaceutical policies: effects of financial incentives for prescribers (2015)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Five Years of Cancer Drug Approvals (2015)Market size and pharmaceutical innovation (2015)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs391 cited
  • 2004The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s344 cited
  • 2007Pharmaceutical Price Controls and Entry Strategies298 cited
  • 2003Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries199 cited
  • 2013Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement153 cited
  • 2006Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?136 cited
  • 2012Effects of Regulation on Drug Launch and Pricing in Interdependent Markets83 cited
  • 2006Prices And Availability Of Biopharmaceuticals: An International Comparison68 cited

Cited by

  • 2012Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context54 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work